Kalvista Pharmaceuticals, INC 10-Q quarterly reports

KalVista Pharmaceuticals reports Q1 2026 results, driven by EKTERLY sales, and announces a definitive agreement to be acquired by Chiesi for $27.00 per share.

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and initial commercial launch of EKTERLY for hereditary angioedema, alongside new financing activities.

KalVista Pharmaceuticals reports its first product revenue following the FDA approval and commercial launch of EKTERLY, an oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals' Q3 2025 report details financial results and provides updates on the regulatory submissions for sebetralstat, its oral on-demand therapy for hereditary angioedema (HAE).

KalVista Pharmaceuticals announced its second quarter 2025 results, highlighted by a $100 million upfront payment from a royalty financing agreement and approximately $56 million in net proceeds from equity offerings.

KalVista Pharmaceuticals reports its Q1 2025 results, highlighting progress in its hereditary angioedema (HAE) treatment program, including the acceptance of its New Drug Application (NDA) by the FDA.

KalVista Pharmaceuticals announced positive topline results from its Phase 3 KONFIDENT trial for sebetralstat and secured approximately $150.1 million in net proceeds from an underwritten offering.